Ann: Full Year Statutory Accounts and Appendix 4E, page-42

Yes, getting some clarity on future directions would be a good outcome.

In the webinar, MM made an interesting comment. She stated that Biotron "was a small compny" and I wonder if she was providing a hint of some sorts. It did not fill me with much enthusiasm, and I do believe that BIT's management has discovered a bit of reality.

You can't just run "positive" trials and talk up prospects before those trials are completed and then hope that someone will take up the ball and run with it.

Webinar was interesting on a number of fronts - but the tone was fairly subdued.